Altering metabolic profiles of drugs by precision deuteration 2: Discovery of a deuterated analog of ivacaftor with differentiated pharmacokinetics for clinical development

Journal of Pharmacology and Experimental Therapeutics

Volumn 362, Issue 2, 2017, Pages 359-367

  Harbeson, Scott L ^a   Morgan, Adam J ^a   Liu, Julie F ^a   Aslanian, Ara M ^a   Nguyen, Sophia ^a   Bridson, Gary W ^a   Brummel, Christopher L ^a   Wu, Lijun ^a   Tung, Roger D ^a   Pilja, Lana ^a   Braman, Virginia ^a   Uttamsingh, Vinita ^a  

^a Drug Metabolism and Pharmacokinetics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DEUTIVACAFTOR; DRUG METABOLITE; IVACAFTOR; AMINOPHENOL DERIVATIVE; DEUTERIUM; QUINOLONE DERIVATIVE;

ADULT; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; EC50; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VITRO STUDY; MALE; MAXIMUM CONCENTRATION; MEASUREMENT PRECISION; NONHUMAN; NORMAL HUMAN; OXIDATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; ANIMAL; CHEMISTRY; DOG; DRUG DEVELOPMENT; DRUG EFFECTS; LIVER MICROSOME; METABOLISM; METABOLOME; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SPRAGUE DAWLEY RAT;

ADMINISTRATION, ORAL; AMINOPHENOLS; ANIMALS; CROSS-OVER STUDIES; DEUTERIUM; DOGS; DRUG DISCOVERY; FEMALE; HUMANS; MALE; METABOLOME; MICROSOMES, LIVER; QUINOLONES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 85027253731     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.117.241497     Document Type: Article

References (30)

1. Aditya S (2012) Ivacaftor in cystic fibrosis: the first disease modifying agent. Int J Basic Clin Pharmacol 1:225-229.
2. Atkins WM and Sligar SG (1987) Metabolic switching in cyctochrome P-450cam: deuterium isotope effects on regiospecificity and the monooxygenase/oxidase ratio. J Am Chem Soc 109:3754-3760.
3. Austedo. (2017) Package insert. Teva Pharmaceuticals USA, North Wales, PA.
4. Baillie TA (1981) The use of stable isotopes in pharmacological research. Pharmacol Rev 33:81-132.
5. Fink A, Sawicki GS, Morgan WJ, Schechter MS, Rosenfeld M, and Marshall BC (2015) Treatment response to ivacaftor in clinical practice: analysis of the US CF Foundation patient registry. Pediatr Pulmonol 50:361 (Abstract 450).
6. Fisher MB, Henne KR, and Boer J (2006) The complexities inherent in attempts to decrease drug clearance by blocking sites of CYP-mediated metabolism. Curr Opin Drug Discov Devel 9:101-109.
7. Guengerich FP (2013) Kinetic deuterium isotope effects in cytochrome P450 oxidation reactions. J Labelled Comp Radiopharm 56:428-431.
8. Halford B (2016) Deuterium swithcheroo breathes life into old drugs. Chem Eng News 94:32-36.
9. Harbeson SL and Tung RD (2011) Deuterium in drug discovery and development. Annu Rep Med Chem 46:403-417.
10. Harbeson SL and Tung RD (2014) Deuterium medicinal chemistry: a new approach to drug discovery and development. Med Chem News (Japan) (2)8-22.
11. Horning MG, Haegele KD, Sommer KR, Norwin J, and Stafford M (1976) Metabolic switching of drug pathways as a consequence of deuterium substitution, in Proceedings of the Second International Conference on Stable Isotopes, October 20-23, 1975, Oak Brook, Illinois (Klein ER and Klein PD eds) pp 41-54, US Government Printing Office, Washington, DC.
12. Jenks WP (1987) Catalysis in Chemistry and Enzymology, Dover Publications Inc., Mineola, NY.
13. Kalydeco. (2015) Package insert. Vertex Pharmaceuticals, Boston, MA.
14. Korzekwa KR, Trager WF, and Gillette JR (1989) Theory for the observed isotope effects from enzymatic systems that form multiple products via branched reaction pathways: cytochrome P-450. Biochemistry 28:9012-9018.
15. Kushner DJ, Baker A, and Dunstall TG (1999) Pharmacological uses and perspectives of heavy water and deuterated compounds. Can J Physiol Pharmacol 77: 79-88.
16. Morgan AJ (2015), inventor, Concert Pharmaceuticals, Inc., assignee. Deuterated CFTR potentiators. U.S. Patent 9,181,192. 10 November 2015.
17. Nelson SD and Trager WF (2003) The use of deuterium isotope effects to probe the active site properties, mechanism of cytochrome P450-catalyzed reactions, and mechanisms of metabolically dependent toxicity. Drug Metab Dispos 31: 1481-1498.
18. Northrop DB (1975) Steady-state analysis of kinetic isotope effects in enzymic reactions. Biochemistry 14:2644-2651.
19. Ong T and Ramsey BW (2015) Update in Cystic Fibrosis 2014. Am J Respir Crit Care Med 192:669-675.
20. Orkambi. (2016) Package insert. Vertex Pharmaceuticals Incorporated, Boston, MA. Paxil. (2012) Package insert. GlaxoSmithKline, Research Triangle Park, NC.
21. Riordan JR (2008) CFTR function and prospects for therapy. Annu Rev Biochem 77: 701-726.
22. Rittenberg D and Schoenheimer R (1937) Deuterium as an indicator in the study of intermediate metabolism: XI. Further studies on the biological uptake of deuterium into organic substances, with special reference to fat and cholesterol. J Biol Chem 121:235-253.
23. Siracusa CM, Ryan J, Burns L, Wang Y, Zhang N, Clancy JP, and Drotar D (2015) Electronic monitoring reveals highly variable adherence patterns in patients prescribed ivacaftor. J Cyst Fibros 14:621-626.
24. Uttamsingh V, Gallegos R, Liu JF, Harbeson SL, Bridson GW, Cheng C, Wells DS, Graham PB, Zelle R, and Tung R (2015) Altering metabolic profiles of drugs by precision deuteration: reducing mechanism-based inhibition of CYP2D6 by paroxetine. J Pharmacol Exp Ther 354:43-54.
25. Uttamsingh V, Pilja L, Grotbeck B, Brummel CL, Uddin N, Harbeson SL, Braman V, and Cassella J (2016) CTP-656 tablet confirmed superiority of pharmacokinetic profile relative to Kalydeco in phase 1 clinical studies. J Cyst Fibros 15:S22 (Abstract WS13.6).
26. Van Goor F, Hadida S, Grootenhuis PD, Burton B, Cao D, Neuberger T, Turnbull A, Singh A, Joubran J, Hazlewood A, et al. (2009) Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci USA 106:18825-18830.
27. Van Goor F, Hadida S, Grootenhuis PD, Burton B, Stack JH, Straley KS, Decker CJ, Miller M, McCartney J, Olson ER, et al. (2011) Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci USA 108:18843-18848.
28. Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA, et al.; TRAFFIC Study Group; TRANSPORT Study Group (2015) Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med 373:220-231.
29. Yang X, Hadida Ruah S, Grootenjuis P, Van Goor FF, Botfield M, and Zlokarnik G (2010), inventors, Vertex Pharmaceuticals, assignee. Modulators of cystic fibrosis transmembrane conductance regulator. International Patent Publication Number WO 2010/108155. 23 September 2010.
30. Zha J, Zhang J and Ordonez C (2011) Pharmacokinetics (PK), metabolism and excretion of [14C] VX-770, a potentiator of cystic fibrosis transmembrane conductance regulator (CFTR), in healthy subjects. J Clin Pharmacol 51:1358-1359 (Abstract 1124131).